Processing aids with the quality and reliability the industry demands
Whether you’re in the business of small or large molecule API manufacture, Dow is here to support you.
Large Molecule (Biologic) API Production
Dow’s TRITON™ and TERGITOL™ surfactants are used to inactivate virus envelopes, lyse cells, and buffer RNA extraction solutions. As the only producer of TRITON™ X-100 (CAS No: 9036-19-5), which has been trusted by the industry for decades, Dow is committed to ensuring reliable supply for our customers.
Contact our technical team today to discuss defoaming, reducing shear stress on cells, and more.
Small Molecule API Production
Dow delivers a wide range of solvents at competitive pricing in every region of the world. We are also prepared to support your business in other ways:
- We have multiple production and storage facilities to give you peace of mind when it comes to supply reliability.
- We will gladly discuss custom inventory options to meet your business continuity needs.
The table below shows some of the most common solvents used in pharma applications but is not intended to be an exhaustive list. Contact us if you have questions regarding any other solvents.
|Solvent Common Name||CAS No|
|CARBITOL™ Solvent, Diethylene Glycol Monoethyl Ether, Ethoxydiglycol||111-90-0|
|Isobutyl alcohol, Isobutanol||78-83-1|
|Isopropyl Alcohol, Isopropanol Anhydrous USP/EP||67-63-0|
|DOWANOL™ EPh NF, Phenoxyethanol||122-99-6|
|Propionic Acid FCC||79-09-4|
|Triethanolamine, Trolamine (TEA)||102-71-6|
|Valeric Acid Ultrapure||109-52-4|
*These products are not produced according to any Pharmacopoeia standards unless specifically noted, nor do we test according to any pharma standard. Dow does not agree to any additional claims outside of those specifically listed in our Sales Specification; it is the responsibility of the customer or end user to determine suitability of our product in each specific application and formulation. Industrial grade solvents may be suitable for some pharmaceutical manufacturing processes as long as no residual product is found in the final pharmaceutical product.